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Abstract
Objective: To identify demographic and clinical risk factors associated with mortality after initiation of antiretroviral therapy
(ART) in a cohort of human immunodeficiency (HIV) infected children in KwaZulu-Natal, South Africa.
Methods: We performed a retrospective cohort study of 537 children initiating antiretroviral therapy at McCord Hospital in
KwaZulu-Natal, South Africa. Data were extracted from electronic medical records and risk factors associated with mortality
were assessed using Cox regression analysis.
Results: Overall there were 47 deaths from the cohort of 537 children initiating ART with over 991 child-years of follow-up
(median 22 months on ART), yielding a mortality rate of 4.7 deaths per 100 child years on ART. Univariate analysis indicated
that mortality was significantly associated with lower weight-for-age Z-score (p,0.0001), chronic diarrhea (p=0.0002),
lower hemoglobin (p=0.002), age ,3 years (p=0.003), and CD4% ,10% (p=0.005). The final multivariable Cox
proportional hazards mortality model found age less than 3 years (p=0.004), CD4 ,10% (p=0.01), chronic diarrhea
(p=0.03), weight-for-age Z-score (,0.0001) and female gender as a covariate varying with time (p=0.03) all significantly
associated with mortality.
Conclusion: In addition to recognized risk factors such as young age and advanced immunosuppression, we found female
gender to be significantly associated with mortality in this pediatric ART cohort. Future studies are needed to determine
whether intrinsic biologic differences or socio-cultural factors place female children with HIV at increased risk of death
following initiation of ART.
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Introduction
Pediatric HIV remains prevalent in sub-Saharan Africa. As of
2009, South Africa alone had more than 280,000 HIV-infected
children [1]. Untreated pediatric HIV infection carries a high
mortality rate [2,3]. However, access to ART in sub-Saharan Africa
has increased dramatically since 2005 [1,4,5,6]. Until recently, few
data were available regarding clinical risk factors associated with
mortality in children after they initiate ART [7,8,9,10,11]. Recent
studies from Southern Africa have consistently found low absolute
CD4 and CD4% at the time of ART initiation to be associated with
early mortality on ART [5,7,8,11]. Additionally, several studies
confirmed that stunting, wasting, anemia, and WHO stage 4
conditions at the time of ART initiation significantly contribute to
early pediatric mortality on ART [5,8,10,11].
Although, gender has not previously been associated with
mortality in these African cohorts, several studies have document-
ed gender discrepancies in response to HIV infection
[12,13,14,15]. Two small studies documented lower HIV RNA
in girls compared to boys after initiation of ART [13,14].
However, an additional study found no difference in viral loads
between the genders [16].
Expanded knowledge of baseline factors associated with early
mortality could improve local guidelines regarding the timing and
choice of ART regimen and help target intensity of medical
surveillance after ART initiation towards those children at highest
risk of early death.
Materials and Methods
Ethics Statement
The protocol was approved by McCord Hospital’s Research
Ethics Committee and the Partners Human Research Committee.
All patients accessing care at McCord Hospital sign a written
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22706consent to have their medical information stored on an electronic
medical record database that is used for clinical and research
purposes.
Study design
We performed a retrospective cohort study using electronic
medical records from HIV infected pediatric patients (#18 years
old) who initiated antiretroviral therapy at McCord Hospital’s
Sinikithemba Clinic in KwaZulu-Natal, South Africa from August
2003 to December 2008. We analyzed clinical and demographic
characteristics at the time of initiation of ART therapy as potential
predictors of mortality.
Study population and standard of care
McCord Hospital is a semi-private, urban hospital providing
care for a mostly Zulu speaking population in Durban, South
Africa. Between August 2003 and December 2008, 537 children
initiated ART at McCord Hospital’s Sinikithemba Clinic. Patients
were followed from the time they initiated ART until they died,
transferred care to another facility, were lost to follow-up, or until
the study end date of May 31, 2009. In this clinical setting,
children were diagnosed with tuberculosis based on a combination
of available clinical, radiographic, microscopic, and contact
information. During the study period, children were initiated on
ART when their HIV disease reached World Health Organization
(WHO) stage 3 or 4 and/or their CD4 percentage was less than
20% in children younger than 18 months, or less than 15% in
children older than 18 months, in accordance with South African
National Treatment Guidelines [17]. Based on national guidelines
in South Africa, children less than 3 years of age received a
Protease Inhibitor (PI)-based first line treatment regimen com-
prised of lopinavir/ritonavir, stavudine, and lamivudine [17].
Children older than 3 years initiated a Non-Nucleotide Reverse
Transcriptase Inhibitor (NNRTI) based treatment regimen
comprised of efaverinez, stavudine, and lamivudine [17]. Accord-
ing to local guidelines routine laboratory monitoring includes
baseline CD4 and 6 monthly CD4 and viral loads [17].
Throughout the duration of the study period, children taking an
efaverinez based regimen who had HIV-TB co-infection did not
have any alterations to their treatment while children receiving
protease inhibitor based treatment were either changed from
lopinavir/ritonavir to ritonavir or received double dosed lopina-
vir/ritonavir.
Data Collection
We evaluated medical records from all patients who were #18
years old when they initiated ART at McCord Hospital’s
Sinikithemba Clinic from August 2003 to December 2008.
TrackCare Software was used to maintain electronic medical
records, which were cross referenced with paper charts. Data were
entered into a Microsoft Access database, and we then reviewed
10% of all medical records for accuracy. Collected data included
age at ART initiation, gender, ART regimen, presence of
tuberculosis (TB) and non-TB opportunistic infections, chronic
diarrhea (longer than 14 days), baseline laboratory results
including absolute and CD4 percentage, and hemoglobin, and
baseline weight-for-age Z-scores (calculated for all children less
than 10 years of age using the WHO macro for STATA; https://
www.who.int/childgrowth/software). Children older than 10
years were assigned a dummy variable for missing weight-for-age
z-score so that they could be included in the multivariable model.
The presence of chronic diarrhea and opportunistic infections
were recorded based on their presence in the electronic medical
record as well as review of the hard copy paper records. If these
conditions were not documented in the electronic medical record
or paper charts they were reported as absent.
Lost to Follow up, Transfers and Deaths. Children were
considered lost to follow up if they did not collect treatment for 3
consecutive months. Attempts were made to contact all children
who were lost to follow up to determine their status. All lost to
follow ups and transfers were censored on the date of their last
visit. Otherwise follow-up time was censored at the end of the
study period. Death events were defined as all-cause deaths
occurring after ART initiation but before the May 31, 2009 end of
the study period. Deaths were confirmed by hospital records or
family interview. Cause of death was determined by the primary
care physician or by verbal autopsy from family members.
Missing Data. In multivariate analysis, only subjects with
complete data were analyzed. In univariate analysis subjects were
included if they had complete data for the covariate of interest. No
data was imputed for this analysis. Since weight-for-age Z-score
was systematically missing for children older than 10 years, two
variables were included simultaneously in the model for Z-score as
a continuous variable and the other as a categorical indicating the
absence of Z-score. Including both variable simultaneously allows
children .10 years to be included in the multivariable model
without imputing values.
Statistical Analysis
Statistical analyses were conducted using SAS statistical
software (Release 9.2, Carey, NC). Time to mortality was assessed
for subjects from the date of ART initiation to the date of death
occurring before May 31, 2009 (end of the study period).
We used Cox proportional hazards regression models to assess
associations between demographic and clinical characteristics and
mortality. We first determined univariate associations between
nine demographic and clinical covariates that, based upon clinical
observations and prior studies, were suspected to be potentially
important correlates of post-ART mortality. Age was stratified into
2 categories (,3 years and $3 years old) to account for the age
related difference in ART treatment regimens. We did not assess
the association between type of ART regimen (Protease Inhibitor
verses Non-Nucleotide Reverse Transcriptor Inhibitor) and
mortality in these analyses because the ART regimen was selected
based on age, and thus these variables were highly correlated
(Pearson correlation coefficient=0.83). Gender was added in a
priori to assess age and sex matched controls. Female gender was
found to violate the proportional hazard assumption of the Cox
model; therefore, was evaluated as a time varying hazard in the
final model. We constructed Kaplan-Meier survival curves
stratified by age and gender and assessed the difference between
the curves using the log rank test. Since CD4 ,15% is required for
initiation of ART in most children in South Africa [17], the data
was highly skewed; therefore, we stratified the CD4 percent
variable at ,10% and $10%. Using the remaining eight variables
assessed in univariate analysis, we constructed a multivariable
mortality model and used the Score Test criterion in combination
with Akaike Information Criterion (AIC) to determine the most
parsimonious model [18].
We evaluated the proportional hazards assumptions for the
variables in the final multivariable mortality model using the
Schoenfeld residuals method. This tests whether the residuals for
each variable are uncorrelated (P.0.05) with the ordering of
times to death events. We found that the female gender was
significantly correlated with death event times (P=0.02). The
other variables were not significantly correlated with death event
times. We therefore further evaluated the proportional hazards
assumption for the female gender variable by assessing it within
Mortality in HIV Infected Children
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as a time-varying covariate with time considered as natural log
of time. This time varying covariate was significant (P=0.03)
after adjusting for the other covariates within the multivariable
model.
Results
Patient Characteristics and Mortality
Demographic and clinical characteristics of the 537 analyzed
subjects are described in Table 1. Forty-seven subjects died during
the study period, with deaths occurring a median of 60 days after
starting ART (range 5 days–2.7 years). The overall mortality in
this cohort was low, with only 4.7 deaths per 100 child years on
ART. Of the 490 surviving subjects, 18 (3.7%) (10 females, 8
males) were lost to medical follow-up and 72 (14.7%) (41 females,
31 males) subjects were no longer followed because they
transferred care to another clinic. Median follow-up for the
surviving subjects was 22 months, with follow-up ranging from 14
days to 5.3 years.
Most of these deaths occurred early; 64% (30) occurred within 3
months, and 83% (39) within 6 months of ART initiation. Only 3
children died after 12 months of ART, accounting for 0.56% of
the entire cohort with a total follow up time in the study of over
991 child-years. Of the early deaths that occurred before 6 months
on ART,28% (11) died of tuberculosis and 18% (7) died of
diarrhea, dehydration or malnutrition. Among the children who
died between 6 months and one year after initiation of ART, all 5
had plasma HIV RNA levels of ,400 copies/ml measured after 6
months on ART. The cause of death was determined to be culture
confirmed tuberculosis in 2 children (40%) (both with multiple
episodes of tuberculosis treatment), severe malnutrition with
chronic diarrhea in 2 children (40%) and unknown in 1 child
(20%). Of the 3 children that died after completing one year of
ART, 2 (66%) died with high levels of viremia on second-line ART
and 1 child died of disseminated tuberculosis.
Table 1. Demographic and Clinical Characteristics.
Baseline Characteristics N Total Complete Cohort Males Females p-value
N 537 261 (48.6%) 276 (51.4%)
Age at ART initiation (median; years) [IQR] 537 6.0 [2.4–9.3] 5.95 [2.23–8.75] 6.25 [3.1–9.7] 0.08
,3 years 149 (27.8%) 80 (30.7%) 69 (25%) 0.15
3–18 years 388 (72.2%) 181 (69.3%) 207 (75%)
CD4 absolute (median; cells/mL)[IQR] 535 226 [70–447] 242 [80–467] 205 [69–438] 0.50
CD4 ,10% 524 250 (47.7%) 126 (49.4%) 124 (46.1%) 0.48
Documented OI at baseline 537 138 (25.7%) 63 (24.1%) 75 27.2%) 0.43
Chronic Diarrhea 537 112 (20.9%) 59 (22.6%) 53 (19.2%) 0.34
Hemoglobin (median; g/dl)[IQR] 482 10.0 [8.9–11] 10 [8.8–10.9] 10.1 [8.9–11.1] 0.37
Weight-for-age z-score{ (median) [IQR] 403 21.4 [22.6–20.5] 21.5 [22.8–20.6] 21.3 [22.4–20.5] 0.14
TB at initiation of ART 537 228 (42.5%) 107 (41.1%) 121 (43.8%) 0.54
NNRTI treatment* 414 (77.1%) 195 (74.7%) 219 (79.4%) 0.22
Deaths 47 (8.8%) 19 (7.3%) 28 (10.1%) 0.29
*20 children in the ,3 year old group were started on NNRTI while all children over 3 years old were initiated on NNRTI based treatment.
{WHO weight-for-age Z-score is only valid for children ,10 years old.
doi:10.1371/journal.pone.0022706.t001
Table 2. Unadjusted Cox Proportional Hazard Ratios for Mortality after Initiating HIV Treatment.
Demographic and Clinical Variables{ n=537
Hazard Ratio (95% Confidence
Interval) 47 death events P value
Age ,3 years 2.42 (1.37–4.30) 0.003
Female gender 1.43 (0.80–2.56) 0.23
Absolute CD4 count (cells/mL) 0.999 (0.998–1.000) 0.05
CD4 ,10% 2.49 (1.33–4.66) 0.005
Hemoglobin (gm/dL) 0.76 (0.63–0.90) 0.002
Opportunistic infection not tuberculosis 1.85 (1.03–3.33) 0.04
Tuberculosis at or after initiation of HIV therapy 1.63 (0.92–2.92) 0.10
Chronic diarrhea 3.02 (1.69–5.39) 0.0002
Weight-for-age Z-score 0.53 (0.43, 0.64) ,0.0001
{Absolute CD4, hemoglobin and weight-for-age Z-score were treated as continuous variables. Reference groups for the binary variables include: Age ,3 years – reference
age 3–18 years; CD4 ,10% - reference CD4 .10%, Opportunistic infection includes children with the presence of candidiasis, Kaposi’s sarcoma, Pneumocystis jiroveci
pneumonia, cryptococcosis, toxoplasmosis, or cryptosporidiosis, while the reference group did not have any of these opportunistic infections; Tuberculosis at or after
initiation or HIV therapy – reference was the absence of HIV-tuberculosis co-infection; chronic diarrhea – reference children not documented to have chronic diarrhea.
doi:10.1371/journal.pone.0022706.t002
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Univariate associations between demographic and clinical
characteristics and mortality are shown in Table 2. Weight-for-
age Z-score (p,0.0001), chronic diarrhea (p=0.0002), lower
hemoglobin (p=0.002), age ,3 years (p=0.003), and CD4%
,10% (p=0.005) were all strongly associated with mortality. The
age stratified Kaplan Meier survival curves for time after initiation
of ART are shown in Figure 1. Non-TB opportunistic infections
(p=0.04) and absolute CD4 count (p=0.05) were also signifi-
cantly associated with death.
Multivariable Assessment of Mortality Risk
A multivariable Cox proportional hazards mortality model was
developed using the following covariates: weight-for-age Z-score,
chronic diarrhea, hemoglobin, CD4%, tuberculosis coinfection,
presence of opportunistic infection, age ,3 years, and gender. The
final model, selected from the best fit model with the lowest AIC
using the Score Test [13], is shown in Table 3. In multivariate
analysis, age, CD4 ,10%, chronic diarrhea, and weight-for-age
Z-score were all shown to be strongly and independently
predictive of mortality. Interestingly, this analysis also revealed a
difference in the survival rate between males and females following
initiation of ART. Although female gender was not significantly
associated with mortality in univariate analysis, it was significantly
associated (p=0.03) with mortality when controlling for age,
weight-for-age Z-score, chronic diarrhea, and CD4%. The
unadjusted Kaplan-Meier graph is illustrated in Figure 2. Female
gender was best described as varying linearly with the natural log
(ln) of time within the multivariable model.
6 Month Viral Response
At six months of ART therapy there were 424 subjects with viral
load data available. There was no significant difference (p=0.56)
in viral suppression rates to ,400 copies/ml between males 170/
198 (86%) and females 199/226 (88%).
Sensitivity Analysis
In order to determine the impact of lost to follow-up, a
sensitivity analysis was performed including the composite
endpoint of lost to follow-up and death. This did not significantly
change any results in the univarite analysis. In the multivariate
analysis only the presence of chronic diarrhea was no longer
significant with a p value of 0.12. Age less than three years
(p=0.006), CD4 ,10% (p=0.016), weight for age Z-score
(p,0.001), and female gender (p=0.007) all remained significant.
Discussion
The increased availability of ART in sub-Saharan Africa has
dramatically improved outcomes for pediatric patients infected
with HIV. However, treatment guidelines and algorithms continue
to evolve, and there is a pressing need for clinical outcomes data to
further refine HIV management strategies for children in resource-
limited settings. There is a particularly pressing need for data
regarding clinical factors that place these children at increased risk
of early mortality despite initiation of ART. Our findings agree
with published data from other African cohorts that age ,3 years,
severely reduced CD4 percent (,10%), chronic diarrhea, and
reduced weight-for-age Z-scores are strongly associated with
mortality among HIV positive children initiating ART
[5,7,8,9,10,11,19,20].
The mortality risk factors identified in this study highlight
several areas for potential improvement in pediatric treatment and
monitoring algorithms. The increased mortality in younger
Figure 1. The age-stratified Kaplan-Meier graph of survival
after ART initiation.
doi:10.1371/journal.pone.0022706.g001
Table 3. Adjusted Cox Proportional Hazard Ratios for
Mortality after Initiating HIV Treatment.
Predictors { n=524*
Hazard Ratio (95%
Confidence Interval) 46
death events P value
Age ,3 years 2.66 (1.37–5.17) 0.004
CD4 ,10% 2.39 (1.21–4.71) 0.01
Chronic diarrhea 1.91 (1.05–3.49) 0.03
Weight-to-age Z-score 0.59 (0.47–0.73) ,0.0001
Female*ln time{ 1.79 (1.05–3.49) 0.03
{Weight-for-age Z-score and Female*ln time were treated as continuous
variables. Reference groups for the binary variables include: Age ,3 years –
reference age 3–18 years; CD4 ,10% - reference CD4 .10%; chronic diarrhea –
reference children not documented to have chronic diarrhea.
*13 subjects were missing one or more of the model’s predictor variables and
were not included in the analysis.
{Female*ln time represents the interaction term of female gender and the
natural log of time in weeks since ART initiation.
doi:10.1371/journal.pone.0022706.t003
Figure 2. The gender-stratified Kaplan-Meier graph of survival
after ART initiation.
doi:10.1371/journal.pone.0022706.g002
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evidence of improved outcomes in infant ART initiation argues for
the early initiation of ART in HIV positive children [21]. In
response, WHO treatment guidelines have recently been altered to
recommend expansion of ART to all infants younger than 24
months and all young children with CD4 percentages lower than
25% [22]. Importantly, the vast majority of deaths in our cohort
occurred prior to the first set of monitoring labs, which are drawn
after six months of therapy per South African guidelines. It would
seem prudent to target children with multiple risk factors to receive
earlier clinical and laboratory follow-up to ensure an adequate
response to therapy. The increased mortality in children with
chronic diarrhea and low weight-for-age Z-score at the time of
initiation of ART indicates the importance of monitoring
nutritional status at the time of ART initiation and argues for
earlier ART initiation in these children. Future studies on early
aggressive nutritional monitoring and interventions could lead to
improved outcomes in children with malnutrition or chronic
diarrhea. An unexpected finding from our study was the increased
risk of mortality observed among females after controlling for
other risk factors. The mortality risk associated with female gender
increased progressively with time after initiation of ART therapy.
It is unclear whether this disparity is attributable to intrinsic
biological differences between the sexes [13,14,23,24,25] or social
differences such as delayed presentation for care, differences in
parental supervision of boys and girls, or devaluation of the female
gender that could place females at a higher risk of mortality after
ART initiation in South Africa. Among adults, females tend to
have lower viral loads early in HIV-1 infection but progress faster
to AIDS for a given viral load than males [15,25,26]. Therefore, it
has been suggested that initiating HAART based on CD4 and
viral load criteria without accounting for gender differences may
disadvantage women [25]. Although pediatric data are limited,
two prior studies have suggested gender differences in HIV viral
loads among children [13,14], which could provide a biologically
plausible basis for our observation of a gender difference in
survival on HAART. This finding has not been seen in other HIV
mortality analyses of African children [5,7,8,9], most of which
utilized smaller cohorts or pooled data from multiple centers.
However, a similar increase in mortality was seen among female
children in the Women and Infants Transmission Study (WITS), a
longitudinal study of HIV-infected children in North America
[14]. In addition, the European Collaborative group found more
rapid disease progression in HIV infected females less than 4 years
old [13]. The published data regarding the impact of gender on
survival in HIV-infected adults are significantly confounded by
differences in healthcare utilization, as several North American
studies have reported lower healthcare utilization and viral
suppression rates among women [27,28,29], while several African
studies have reported better health utilization and outcomes
among HIV positive women on ART [30,31,32,33,34]. However,
data from adult studies may not be generalizable to young girls,
who are dependent on adult caregivers for accessing clinic services.
Therefore, local societal devaluation of female children may place
them at unique risk for poor outcomes on ART.
Although tuberculosis co-infection was not significantly associ-
ated with mortality in this analysis, this cohort did exhibit a high
incidence of tuberculosis infections and TB was a major
contributor to deaths. The high incidence of TB may represent
over diagnosis and overlap with lymphocytic interstitial pneumo-
nitis [35]. Given the clinical setting many of these were not
bacteriologically confirmed cases tuberculosis; however, represent-
ed clinical diagnosis based on symptoms, radiography, and contact
information. This highlights the pressing need for improved
diagnostics for pediatric tuberculosis infections.
One limitation of our study is that it assesses a single cohort of
HIV positive children from KwaZulu-Natal, South Africa, and a
relatively small number of subjects (8.8%) died during the study
period. It is possible that larger studies with increased statistical
power may identify other risk factors that significantly predict
mortality after initiation of ART in pediatric HIV patients. Given
the small number of children lost to follow-up (LTFU), sensitivity
analysis using the composite endpoint of LTFU and mortality did
not significantly alter the major findings of this study. In addition,
this study was located in a semi-private institution which had
nominal user fees of R50 (approximately $7 USD) per month
which could result in a selection bias toward a wealthier
population. In contrast to many sub-Saharan pediatric popula-
tions, our cohort generally had access to daily meals and water, as
well as medical care at a semi-private clinic, and thus our results
may not be generalizable to more impoverished settings.
Further studies are needed to define gender differences in the
biological manifestations of HIV infection in boys and girls, and to
determine the relationship between gender and survival among
children receiving treatment for HIV infection. Our expanding
knowledge of the risk factors associated with mortality in HIV
infected children on ART can help to further refine HIV
treatment guidelines and monitoring practices.
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